DongC, LiuZ, WangF. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr Med Chem, 2014; 21:139.
2.
DasT, PillaiMRA. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol, 2013; 40:23.
3.
BreemanWAP, de JongM, VisserTJ, et al.Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging, 2003; 30:917.
4.
DasT, ChakrabortyS, KallurKG, et al.Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: The Indian experience. Cancer Biother Radiopharm, 2011; 26:395.
5.
World Health Organization. Guidelines on Good Manufacturing Practices for radiopharmaceutical products, Annex 3. WHO Technical Report Series, No. 908, 2003.
6.
KwekkeboomDJ, BakkerWH, KooijPPM, et al.[177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med Mol Imaging, 2001; 28:1319.
7.
KunikowskaJ, KrolickiL, Hubalewska-DydejczykA, et al.Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: Which is a better therapy option?. Eur J Nucl Med Mol Imaging, 2011; 38:1788.
8.
DasT, BhadwalM, BanerjeeS, et al.Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. J Radioanal Nucl Chem, 2014; 299:1389.
